At Marina we are focused on realizing the potential of RNAi-based therapeutics through the development of multiple broad-based, state-of-the-art drug discovery platforms built upon industry leading expertise in RNA chemistry, microbiology and oligonucleotide delivery. We bring optimal value to our partners, shareholders and ultimately to patients through the discovery and development of RNAi-based therapeutics to treat critical unmet medical needs.
Therapeutic Platform
We are using multiple RNAi drug discovery engines, tkRNAi and tauRNAi, to develop cutting-edge, first-in-class therapeutics for diverse and commercially valuable disease targets.Learn More
Upcoming Clinical Trial
Marina Biotech’s first therapeutic candidate, CEQ508 for the treatment of Familial Adenomatous Polyposis (FAP), is expected to enter into clinical trials in second half of 2010. Learn More
Latest News & Events
MDRNA has merged with Cequent Pharmaceuticals to become Marina Biotech - focused on accelerating RNAi-based therapeutics. Learn More